Autoimmune autonomic ganglionopathy (AAG) is an autoimmune disease in which antibodies target the nicotinic acetylcholine receptor (AChR) in the autonomic ganglia, resulting in dysfunction of the sympathetic, parasympathetic, and enteric nervous systems [1]. The most commonly reported symptoms of AAG include orthostatic hypotension and gastrointestinal dysmotility, but patients can also experience urinary retention, anhidrosis, dry mouth, erectile dysfunction, and an impaired pupillary light reflex [2]. In patients with intestinal pseudo-obstruction, autopsy can reveal infiltrates of lymphocytes in the gastric and intestinal myenteric plexuses [3]. In 2000, Vernino first proposed AAG and determined its pathogenic antibodies—ganglion nAChR antibodies [4]. The acetylcholine receptor on the autonomic ganglia is a transmembrane pentamer consisting of two α3 subunits and three β4 subunits. Pathogenic antibodies bind mainly to the α3 subunit. A few bind to the β4 subunits [2]. Higher antibody levels (> 0.4 nmol/L) are associated with more severe autonomic dysfunction [5]. Patients with AAG can have extra-autonomic manifestations, including psychiatric symptoms, sensory disturbances, and endocrine disorders [1]. A diagnosis of AAG often suggests the need for screening for potential autoimmune diseases or tumors. Approximately 15% of patients may have tumors (small cell lung cancer, thymoma, or adenocarcinoma) [2]. The first-line treatments are intravenous immunoglobulin (IVIG) and plasma exchange. Additionally, steroids, mycophenolate mofetil (MMF), azathioprine, and rituximab might be effective [6, 7]. Lowering antibody levels to physiological levels through immunotherapy can alleviate clinical symptoms [8].
Myasthenia gravis (MG) is an autoimmune neuromuscular disease characterized by muscle weakness and fatigue. Approximately 80–85% of patients have IgG antibodies specific to the muscle nAChR at the neuromuscular junction. The muscle nAChR has two α1 subunits, along with the β1, δ, and γ or ε subunits. The IgG antibodies target the α1 subunit [9].
Anzeige
We report the case of a patient with antibody-confirmed AAG whose condition improved after immunotherapy. However, after 14 months, the patient developed ocular MG and was found to have antibodies against muscle nAChRs. This case indicates that for patients with AAG, follow-up is important to screen for other autoimmune diseases, including MG.
Case report
A 49-year-old woman presented with constipation, which she had experienced since February 2022. Her defecation frequency changed from once a day to every 2–3 days, without nausea or vomiting. In March 2022, she developed orthostatic hypotension and experienced two episodes of syncope while standing. She also reported blurry vision in both eyes and reduced sweating in extremities and trunk. In April 2022, she experienced dizziness upon sitting. In the local hospital, the patient exhibited orthostatic hypotension in tilt table test. Her anal sphincter electromyography were normal. A low-amplitude sympathetic skin response was observed in both hands and feet. Anti-nuclear antibodies (ANAs) were 1:1000. Cerebrospinal fluid tests and enhanced MRI of brain and spine were normal. Symptomatic treatment with midodrine was initiated, along with lifestyle interventions. However, the patient continued to experience recurrent syncope upon standing, as well as difficulty in urination, dry mouth, and fatigue. She was admitted to our hospital.
Physical examination revealed significantly elevated blood pressure in the supine position (181/105 mmHg) and low blood pressure upon standing (78/64 mmHg) after 3 min, with decreased heart rate variability (69–74 beats per minute). The right pupil showed a sluggish response to light. There was decreased sensation to pinpricks in a glove-and-stocking pattern. The patient had a history of three episodes of encephalomyelitis from 2017 to 2019, during which ANA positivity was identified. Improvement was observed with steroids. She was treated with azathioprine for 16 months at a dose of 100 mg per day. The patient reported dry mouth and hair loss. Personal and family history were normal.
After admission, ANA with a titer of 1:640 in a homogeneous pattern, anti-nucleosome antibody (12.3 AU/ml), anti-mitochondrial M2 antibody (57.7 AU/ml), SP100, anti-parietal cell antibody (1:320), anti-B2-glycoprotein (18.7 AU/ml), Coombs test (+), and low complement levels (C3, 55.7 mg/dL; C4, 7.7 mg/dL) were observed. Tumor biomarkers and M protein were negative. Enhanced CT revealed incomplete thymic involution without evidence of tumor (Supplementary Fig. 1). An SLE diagnosis, according to the EULAR/ACR 2019 classification criteria, was made on the basis of the presence of clinical (noncicatricial alopecia, nervous system involvement) and immunological criteria (ANA and antiphospholipid antibody positivity and low complement levels). In stomatology and ophthalmology consultations, no evidence of Sjögren’s syndrome was noted. 131I-MIBG myocardial scintigraphy showed a normal heart-to-mediastinum ratio (Supplementary Fig. 2). Electromyography showed no abnormalities in nerve conduction velocities or F waves. The patient reported significant weakness and fatigue in addition to obvious orthostatic hypotension, and a repetitive nerve stimulation (RNS) test revealed no decrements in amplitudes to low- or high-frequency stimulation. High titers of ganglion nAChR antibodies (0.48 nmol/L; normal, < 0.02 nmol/L) were observed in radioimmunoassay (RIA).
Anzeige
This patient was diagnosed with AAG. Immunotherapy, including steroid pulse therapy, IVIG, and orally administered cyclophosphamide, was initiated. After discharge, the patient was able to resume household chores and did not experience any further syncope episodes. After 6 months of treatment, with a cumulative dose of 10.5 g of cyclophosphamide, repeat ANA testing yielded negative results, and the patient gradually tapered and discontinued symptomatic medications.
However, at the ninth month after discharge (April 2023), the patient developed fluctuating ptosis of the right eyelid. One month later, the patient developed diplopia. Physical examination revealed complete occlusion of the right eyelid and limited upward gaze of the right eye. Upward gaze elicited vertical diplopia. RNS showed a decrease in the amplitude of the response of the left facial nerve to low-frequency stimulation. Muscle AChR antibody positivity (3.72 nmol/L) was noted, along with decreased titers of ganglion AChR antibodies (0.27 nmol/L). Cyclophosphamide was discontinued. The patient was prescribed 30 mg orally administered prednisone per day and 1.5 g orally administered MMF per day and resulted in complete remission of symptoms (Fig. 1).
Whether the occurrence of both AAG and MG in a patient is due to cross-immunity or the presence of two pathogenic antibodies is unclear. Ganglion AChRs and muscle AChRs are both members of the nicotinic AChR superfamily. Nicotinic AChRs are a class of pentameric structures formed by the assembly of five subunits into a ring-like structure. The primary immunogenic region recognized by AAG-specific antibodies is the α3 subunit of ganglion AChR; however, MG-specific antibodies recognize the α1 subunit of muscle AChR. Previous studies have shown that the α3 and α1 subunits have 60% structural similarity but differ in immunogenicity (Supplementary Fig. 3). Lennon et al. reported that rabbits passively immunized against the α3 subunit exhibited antibodies against other subunits of acetylcholine receptors, including α1 subunit [10]. In serum samples from patients with MG and AAG, antibody cross-reactivity between AChRs with different α subunits is uncommon and generally weak [11].
Although the structures of the two antibodies are similar and these antibodies can coexist, the combination of AAG and MG is extremely rare. Miglis et al. reported the case of a patient with antibody-confirmed AAG and elevated levels of muscle AChR antibodies who did not meet clinical or electrodiagnostic criteria for MG, suggesting that this patient’s muscle nAChR antibodies seropositivity was a false positive [12]. Lennon et al. [13] reported cases of seven patients who had MG with subacute autonomic failure. Among them, three patients had antibodies against both muscle AChRs and ganglionic AChRs. All three patients had thymomas. The autonomic symptoms were present simultaneously or after the MG symptoms. In contrast, our patient presented with pure autonomic symptoms for 14 months before she developed fluctuating ptosis. This finding indicates that when a patient with immune system abnormalities develops AAG, long-term follow-up is important for assessing the occurrence of other autoimmune diseases, including MG. Li et al. screened for muscle AChR antibodies in 95 patients with AAG and found that only three were positive. Patients carrying both antibodies had no MG symptoms [14]. Nonetheless, there is a case report documenting the coexistence of AAG and MG in a patient with non-small cell lung cancer [15].
Gastrointestinal symptoms in patients with MG and autonomic neuropathy have been reported [3]. Rakocevic et al. reported a case report and review of 12 previous cases of patients with intestinal pseudo-obstruction and MG who were positive for both antibodies. Thymoma may be related to antibodies against neuronal nicotinic receptors in the autonomic ganglia. In our case, the patient’s gastrointestinal symptoms were relatively mild. Gastrointestinal motility endoscopy was suggested, but the patient declined further examination for financial reasons.
In our case, various combinations of autoimmune neurological diseases emerged at different stages of the patient’s disease course, including encephalomyelitis, AAG, and MG. The patient was considered to exhibit antibody epitope spreading and immune generalization in the context of an immune background and incomplete thymic involution. Following treatment with rituximab and thymectomy can be considered.
Conclusion
In patients with acute/subacute onset of autonomic dysfunction, ganglionic AChR antibody testing is recommended. Ganglion antibody titers can be monitored to evaluate the effectiveness of immunotherapy. Patients with various autoimmune antibodies should be screened for underlying tumors and autoimmune diseases. Understanding the structure and function of ganglion AChRs and muscle AChRs in patients with coexistent AAG and MG is important.
Declarations
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.
Anzeige
Ethical approval
Patient consent was obtained, and ethics approval was obtained from Peking Union Medical College Hospital protocol I-22PJ820. Informed consent Informed consent from the patient was also obtained.
Consent for publication
Available and approved.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Nakane S, Mukaino A, Higuchi O, Watari M, Maeda Y, Yamakawa M, Nakahara K, Takamatsu K, Matsuo H, Ando Y (2018) Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Rev Neurother 18:953–965PubMed
2.
Nakane S, Mukaino A, Higuchi O, Yasuhiro M, Takamatsu K, Yamakawa M, Watari M, Tawara N, Nakahara KI, Kawakami A, Matsuo H, Ando Y (2020) A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy. J Autoimmun 108:102403PubMed
3.
Rakocevic G, Barohn R, McVey AL, Damjanov I, Morte PD, Vernino S, Lennon V (2003) Myasthenia gravis, thymoma, and intestinal pseudo-obstruction: a case report and review. J Clin Neuromuscul Dis 5:93–95PubMed
4.
Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA (2000) Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 343:847–855PubMed
5.
Cutsforth-Gregory JK, McKeon A, Coon EA, Sletten DM, Suarez M, Sandroni P, Singer W, Benarroch EE, Fealey RD, Low PA (2018) Ganglionic antibody level as a predictor of severity of autonomic failure. Mayo Clin Proc 93:1440–1447PubMed
6.
Hayashi T, Nakane S, Mukaino A, Higuchi O, Yamakawa M, Matsuo H, Kimura K (2022) Effectiveness of treatment for 31 patients with seropositive autoimmune autonomic ganglionopathy in Japan. Ther Adv Neurol Disord 15:17562864221110048PubMedPubMedCentral
7.
Gupta A, Harris S, Vernino S, Naina HV (2015) Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy. Clin Auton Res 25:255–258PubMed
8.
Golden EP, Vernino S (2019) Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clin Auton Res 29:277–288PubMed
Lennon VA, Ermilov LG, Szurszewski JH, Vernino S (2003) Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 111:907–913PubMedPubMedCentral
11.
Vernino S, Lindstrom J, Hopkins S, Wang Z, Low PA, Muscle Study Group (2008) Characterization of ganglionic acetylcholine receptor autoantibodies. J Neuroimmunol 197:63–69PubMedPubMedCentral
12.
Miglis MG, Racela R, Kaufmann H (2011) Seropositive myasthenia and autoimmune autonomic ganglionopathy: cross reactivity or subclinical disease? Auton Neurosci 164:87–88PubMed
13.
Vernino S, Cheshire WP, Lennon VA (2001) Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci 88:187–192PubMed
14.
Li Y, Jammoul A, Mente K, Li J, Shields RW, Vernino S, Rae-Grant A (2015) Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. Muscle Nerve 52:386–391PubMed
15.
Peltier AC, Black BK, Raj SR, Donofrio P, Robertson D, Biaggioni I (2010) Coexistent autoimmune autonomic ganglionopathy and myasthenia gravis associated with non-small-cell lung cancer. Muscle Nerve 41:416–419PubMedPubMedCentral
Cannabis könnte bei jüngeren Menschen, die schon einmal wegen eines akuten Koronarsyndroms behandelt wurden, das Risiko für weitere kardiovaskuläre Ereignisse deutlich erhöhen. Hinweise hierfür finden sich in einer retrospektiven Studie aus Frankreich.
Plötzlich auftretende Ataxie, Diplopie oder Hörverlust – lassen sich solche Symptome bei Männern nicht erklären, kann sich eine Serumuntersuchung auf neuronale Antikörper lohnen. Die sind mitunter das erste Zeichen eines testikulären Tumors und für den Tumortyp charakteristisch.
In einer Studie sind die Wirkungen von Cladribin und S1P-Modulatoren bei therapienaiven Patienten mit schubförmig remittierender multipler Sklerose verglichen worden – mit gemischtem Ergebnis.
IDH (Isocitrat-Dehydrogenase)-Mutationen sind bei Gliomen im Erwachsenenalter ein wichtiger prognostischer und prädiktiver Faktor und zugleich ein ideales Target für eine zielgerichtete Therapie. Mittlerweile gibt es mit Vorasidenib eine zugelassene Behandlungsoption.
